Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexlansoprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 4/20 | 0.60 |
| ▸ | ATP4B known ✓ | P51164 | 4/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | WDR5 | P61964 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.60 |
| ▸ | SARM1 | Q6SZW1 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.60 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.60 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.60 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.60 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lansoprazole SCHEMBL1067267 | 1.00 | CYP2C9 (0.62) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29353881 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL1559598 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL29353345 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL22366 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29750802 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29598842 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL44975 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL8597994 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL29358567 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2277510-B1 | Controlled release preparation | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-26 | — | — | EP | disclosed |
| EP-1602362-B1 | DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE | TAKEDA PHARMACEUTICAL (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| US-8980322-B2 | Controlled release composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8784885-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20140186449-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140186448-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2014-07-03 | — | — | US | disclosed |
| US-8722084-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-8449911-B2 | Drug composition having active ingredient adhered at high concentration to spherical core | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1553929-B1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-20060013868-A1 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1607088-A1 | CONTROLLED RELEASE COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2005-12-21 | — | — | EP | disclosed |
| EP-1602362-A1 | DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE | Takeda Pharmaceutical Company Limited (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-20050222210-A1 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1553929-A2 | CONTROLLED RELEASE PREPARATION | Takeda Pharmaceutical Company Limited (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1513527-A1 | PRODRUGS OF IMIDAZOLE DERIVATIVES, FOR USE AS PROTON PUMP INHIBITORS IN THE TREATMENT OF E.G. PEPTIC ULCERS | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20040248941-A1 | Benzimidazone compound, process for producing the same, and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1437352-A1 | BENZIMIDAZOLE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004035020-A2 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003105845-A1 | PRODRUGS OF IMIDAZOLE DERIVATIVES, FOR USE AS PROTON PUMP INHIBITORS IN THE TREATMENT OF E.G. PEPTIC ULCERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222210-A1 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | SI, VIP, PGC | ATP4A 192/4885ATP4B 179/4885CYP2C9 44/4885 |
| US-20040248941-A1 | Benzimidazone compound, process for producing the same, and use thereof | SI, MLNR, FABP2 | ATP4A 1187/4885ATP4B 1461/4885CYP2C9 59/4885 |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | ATP4A 1891/4885ATP4B 1479/4885CYP2C9 410/4885 |
| US-20060013868-A1 | Controlled release preparation | SLC18A1, MLN, GCG | ATP4A 1891/4885ATP4B 1479/4885CYP2C9 410/4885 |
| US-20140186449-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | ATP4A 1891/4885ATP4B 1479/4885CYP2C9 410/4885 |
| US-20140186448-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | ATP4A 1891/4885ATP4B 1479/4885CYP2C9 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.